See more : Greenland Resources Inc. (GRLRF) Income Statement Analysis – Financial Results
Complete financial analysis of LumiraDx Limited (LMDXW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of LumiraDx Limited, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Panoro Minerals Ltd. (PML.V) Income Statement Analysis – Financial Results
- Atrium Mortgage Investment Corporation (AMIVF) Income Statement Analysis – Financial Results
- Ceres Acquisition Corp. (CERWF) Income Statement Analysis – Financial Results
- eREX Co.,Ltd. (ERXCF) Income Statement Analysis – Financial Results
- Prime People Plc (PRP.L) Income Statement Analysis – Financial Results
LumiraDx Limited (LMDXW)
About LumiraDx Limited
LumiraDx Limited operates as a point of care diagnostic company. It focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. The company was formerly known as Point of Care Testing Limited and changed its name to LumiraDx Ltd in January 2018. LumiraDx Limited was incorporated in 2002 and is based in London, the United Kingdom.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 254.48M | 421.43M | 139.15M | 23.14M |
| Cost of Revenue | 289.78M | 269.89M | 86.21M | 14.32M |
| Gross Profit | -35.30M | 151.54M | 52.95M | 8.82M |
| Gross Profit Ratio | -13.87% | 35.96% | 38.05% | 38.11% |
| Research & Development | 141.63M | 130.22M | 107.54M | 86.55M |
| General & Administrative | 0.00 | 130.52M | 46.13M | 37.29M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 144.52M | 130.52M | 46.13M | 37.29M |
| Other Expenses | 0.00 | 36.20M | 0.00 | 0.00 |
| Operating Expenses | 287.32M | 296.94M | 153.67M | 123.84M |
| Cost & Expenses | 575.92M | 566.83M | 239.87M | 138.16M |
| Interest Income | 10.39M | 165.43M | 581.00K | 1.98M |
| Interest Expense | 134.56M | 117.94M | 31.60M | 17.19M |
| Depreciation & Amortization | 33.29M | 25.71M | -17.72M | -12.17M |
| EBITDA | -273.54M | 45.74M | -118.44M | -127.19M |
| EBITDA Ratio | -107.49% | 10.85% | -85.11% | -549.62% |
| Operating Income | -321.45M | 20.02M | -100.72M | -115.02M |
| Operating Income Ratio | -126.32% | 4.75% | -72.38% | -497.02% |
| Total Other Income/Expenses | -121.84M | 47.49M | -150.22M | -27.63M |
| Income Before Tax | -443.29M | -97.92M | -250.94M | -142.65M |
| Income Before Tax Ratio | -174.20% | -23.24% | -180.34% | -616.41% |
| Income Tax Expense | 4.32M | 2.84M | -9.95M | -9.54M |
| Net Income | -449.20M | -100.76M | -241.00M | -133.11M |
| Net Income Ratio | -176.52% | -23.91% | -173.19% | -575.18% |
| EPS | -1.59 | -0.62 | -0.95 | -0.53 |
| EPS Diluted | -1.59 | -0.62 | -0.95 | -0.53 |
| Weighted Avg Shares Out | 282.24M | 162.79M | 252.70M | 252.70M |
| Weighted Avg Shares Out (Dil) | 282.24M | 163.26M | 252.70M | 252.70M |
Source: https://incomestatements.info
Category: Stock Reports